Cargando…

A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment

PURPOSE: Brolucizumab has high efficacy in retinal fluid resolution and provides the possibility for longer dosing intervals in the treatment of neovascular age-related macular degeneration. However, brolucizumab has been associated with events of retinal vasculitis and retinal vascular occlusion ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holz, Frank G., Iida, Tomohiro, Maruko, Ichiro, Sadda, SriniVas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Retina 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387760/ https://www.ncbi.nlm.nih.gov/pubmed/35994582 http://dx.doi.org/10.1097/IAE.0000000000003556

Ejemplares similares

Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic
por: Corradetti, Giulia, et al.
Publicado: (2020)

Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration
por: Kuranami, Ai, et al.
Publicado: (2023)

Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab
por: Corradetti, Giulia, et al.
Publicado: (2020)

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
por: Tan, Colin S, et al.
Publicado: (2022)

Choriocapillaris Flow Deficits and Treatment-Naïve Macular Neovascularization Secondary to Age-Related Macular Degeneration
por: Scharf, Jackson M., et al.
Publicado: (2020)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Brolucizumab for macular degeneration
Publicado: (2020)

Type 3 macular neovascularization in a patient with pentosan polysulfate maculopathy
por: Bousquet, Elodie, et al.
Publicado: (2022)

Optical Coherence Tomography Angiography of the Choriocapillaris in Age-Related Macular Degeneration
por: Scharf, Jackson, et al.
Publicado: (2021)

Blood flow pattern in eye before development of type 3 macular neovascularization
por: Yamaguchi, Saya, et al.
Publicado: (2023)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study
por: Maruko, Ichiro, et al.
Publicado: (2021)

Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis
por: Sadda, SriniVas, et al.
Publicado: (2022)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
por: Bae, Ki Woong, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan, Colin S, et al.
Publicado: (2017)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis
por: Hänsli, Christof, et al.
Publicado: (2023)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
por: Joshi, Shrinivas, et al.
Publicado: (2023)

Focus on external limiting membrane and ellipsoid zone in diabetic macular edema
por: Saxena, Sandeep, et al.
Publicado: (2021)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
por: Zakaria, Nadia, et al.
Publicado: (2022)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
por: Abdin, Alaa Din, et al.
Publicado: (2022)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Long-term characteristics of exudative age-related macular degeneration in Japanese patients
por: Saito, Masaaki, et al.
Publicado: (2021)

Reverse engineering for reconstructing baseline features of dry age-related macular degeneration in optical coherence tomography
por: Wang, Shuxian, et al.
Publicado: (2022)

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map
por: Khanani, Arshad M., et al.
Publicado: (2021)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
por: Zubricky, Ryan, et al.
Publicado: (2023)

Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
por: Ueji, Natsuki, et al.
Publicado: (2023)

Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis
por: Siddiqui, Zasim Azhar, et al.
Publicado: (2022)

Risk Factors for Progression of Age-Related Macular Degeneration: Population-Based Amish Eye Study
por: Nittala, Muneeswar G., et al.
Publicado: (2022)

Choriocapillaris Impairment Is Associated With Delayed Rod-Mediated Dark Adaptation in Age-Related Macular Degeneration
por: Kar, Deepayan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sqpruh8hs2i2d5m7pupnshh46s